Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-5111 in Advanced HER2-positive Solid Tumors
NCT04029922Phase 1Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Nov 2019
- Primary completion
- Feb 2023
- Modality
- Immunotoxins, Peptide-Drug Conjugates, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label trial of MT-5111 in HER2-positive solid tumor, breast cancer, gastric cancer (GC) and 1 more (2 arms), sponsored by Molecular Templates, Inc. Primary endpoints: Maximum Tolerated Dose and Safety and Tolerability. Started Nov 2019; status: terminated.
02
Drugs
MT-5111
03
Conditions
HER2-positive solid tumorbreast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04029922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029922.